Therapeutic and prophylactic potential. The breadth and striking antiviral function of virus elimination triggered by lectins such as CV-N argues for a potential therapeutic and/or prophylactic utility. The capacity to irreversibly inactivate infectious SARS-CoV-2 by lectins is particularly compelling for its potential use, as well as the possibility of being employed in noninvasive and environmental roles (e.g. mask modifications or air filtration). Further, the precedent for nasal sprays as a prophylactic strategy raises another possibility for the use of lectins in prevention strategies. The modified lectin Q-GRFT is currently in clinical trials as a nasal spray for the prevention of SARS-CoV-2 infection, with two of them successfully completed , and one dose escalation trial currently recruiting . It will be critical to expand the functional and structural analysis for the irreversibility effect described here, to better understand the potential breadth of utility of lectins in antiviral treatment and prophylaxis.